Browse Category

Pharmaceuticals 7 January 2026 - 9 January 2026

Merck Stock (MRK): MMR Split Move Prolongs Cost Review, Delays Quick Revenue Gain
Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon stock dips as Amazon Pharmacy adds Novo Nordisk’s Wegovy pill, with $25 insured pricing

Amazon Pharmacy said it now offers Novo Nordisk’s Wegovy pill through insurance plans and a cash-pay option, widening its push into prescription drugs as demand for weight-loss treatments spreads beyond injections. Eligible customers with commercial insurance may pay as little as $25 for a one-month supply, while customers without insurance can buy the pill starting at $149 per month; U.S. regulators approved the 25-milligram semaglutide pill in December, the company said. Amazon.com shares were down 0.7% at $244.58 in early New York trade.
9 January 2026
···
Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk (NVO) stock rises premarket as Canada platform touts India-sourced Ozempic

Novo Nordisk’s U.S.-listed shares gained 1.4% to $57.34 in premarket trading on Friday after the company rejected claims involving SaveRxCanada.to, a Canadian online pharmacy platform that says it offers India-sourced Ozempic to U.S. patients. SaveRxCanada.to said the pens start at about $280 each, compared with typical U.S. retail prices of $900 to $1,100. A Novo spokesperson said: “We have no customer or partner relationship with this company/platform, and Ozempic from India has not been provided to them.”
9 January 2026
···
Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer stock price today: PFE ticks up after 340B court block as drug-pricing scrutiny returns

Pfizer Inc shares rose 0.3% to $25.36 on Thursday after a U.S. appeals court blocked a Trump administration pilot that would have changed how safety-net hospitals pay for some medicines. The program covered the first 10 drugs heading into Medicare price negotiations, including Pfizer and Bristol Myers Squibb’s blood thinner Eliquis, and the American Hospital Association said it would have a “devastating effect.” Reuters
8 January 2026
··
Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros stock rises in premarket after $36,000-a-vial Yartemlea price is set

Omeros Corp shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy. “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters
8 January 2026
··
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck & Co shares edged down in after-hours trading on Wednesday after U.S. health officials updated the childhood immunization schedule and moved to a single dose for the human papillomavirus vaccine, a change that could pressure demand for Merck’s Gardasil shot. The stock was down about 0.2% at $108.60, after trading between $107.99 and $111.42 in the regular session. HHS.gov
8 January 2026
····
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines, saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost patent protection. Reuters+1
8 January 2026
····
Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck stock slips after Cidara tender offer; $9 billion R&D hit and HPV schedule shift in focus

Merck & Co shares were down about 0.3% at $108.59 in afternoon trade on Wednesday after the drugmaker said it had completed its cash tender offer for Cidara Therapeutics and expected to finish the acquisition through a merger later in the day. The company said the deal will be treated as an asset acquisition, lifting 2026 research and development expense by about $9.0 billion and cutting earnings per share by roughly 30 cents in the first 12 months. “The acquisition of Cidara strengthens and complements our expanding respiratory portfolio,” Chief Executive Robert M. Davis said. Merck.com
7 January 2026
·····
GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle

GSK said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than 1,800 patients across 29 countries. Chief Scientific Officer Tony Wood called the readout a “major advance”, and GSK said it defines a functional cure as losing a key viral protein and having no detectable virus DNA for at least 24 weeks after treatment ends. GSK
7 January 2026
··
1 … 24 25 26 27 28 … 47
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Uber

NYSE: UBER 93 / 100
#3 BUY ON WEAKNESS

Taiwan Semiconductor

NYSE: TSM 91 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 88 / 100
#5 BUY THE RESET

Ferguson

NYSE: FERG 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.